Imlygic
Talimogene laherparepvec (T-VEC) — Oncolytic Virus Immunotherapy for Melanoma
Quick Facts
Key Takeaways
- Imlygic is the first FDA- and EMA-approved oncolytic virus therapy, derived from a modified herpes simplex virus type 1 (HSV-1), used to treat unresectable advanced melanoma that has spread to the skin or lymph nodes.
- The drug is injected directly into tumors at a medical facility. Treatment begins with a lower concentration dose (106 PFU/ml), followed by higher doses (108 PFU/ml) every two weeks for at least six months.
- Common side effects include flu-like symptoms, fatigue, fever, chills, injection site reactions, nausea, and muscle pain, which typically resolve within 72 hours after each treatment session.
- Imlygic can potentially spread to close contacts through bodily fluids. Injection sites must be covered with airtight dressings, and precautions should be maintained for 30 days after the last dose.
- Patients with severely compromised immune systems must not receive Imlygic. Special precautions apply for pregnant women, breastfeeding mothers, and people who have never had herpes infection before.
What Is Imlygic and What Is It Used For?
Imlygic represents a groundbreaking approach to cancer treatment known as oncolytic immunotherapy. Unlike traditional chemotherapy or radiation, Imlygic harnesses the power of a genetically modified virus to attack cancer cells directly. The active ingredient, talimogene laherparepvec, is derived from herpes simplex virus type 1 (HSV-1)—the virus commonly responsible for cold sores. However, the virus has been significantly altered in the laboratory to make it both safer and more effective against cancer.
The genetic modifications to the HSV-1 virus serve two critical purposes. First, the virus has been engineered to replicate far more efficiently inside tumor cells than in normal, healthy cells. When Imlygic is injected into a melanoma tumor, the modified virus enters the cancer cells, multiplies within them, and eventually causes these cells to rupture and die. This process is known as oncolysis. Second, the virus has been modified to produce granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that recruits and activates the body's immune cells, helping the immune system recognize and destroy tumor cells not only at the injection site but potentially throughout the body.
Imlygic is specifically indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in adult patients with melanoma that has recurred after initial surgery. In clinical trials, the medication demonstrated the ability to shrink injected tumors and, in some cases, tumors at distant sites that were not directly injected. This phenomenon, sometimes called an abscopal effect, underscores the immunological component of Imlygic's mechanism of action.
It is important to understand that Imlygic has not been shown to improve overall survival or to have a significant effect on visceral metastases—meaning melanoma that has spread to internal organs such as the lungs, liver, or brain. The EMA-approved indication is for melanoma that has spread in the skin or to lymph nodes (Stage IIIB, IIIC, and IVM1a), and the treatment is most appropriate for patients with accessible, injectable tumors.
Imlygic was first approved by the U.S. Food and Drug Administration (FDA) in October 2015 and by the European Medicines Agency (EMA) in December 2015. It is manufactured by Amgen and remains the only approved oncolytic virus therapy for melanoma treatment as of 2026. The drug is available only through healthcare facilities and must be administered by trained medical professionals.
What Should You Know Before Receiving Imlygic?
Contraindications
There are specific situations where Imlygic must not be used. Your healthcare provider will carefully assess whether this treatment is appropriate for you before starting therapy.
Do Not Receive Imlygic If:
- You are allergic to talimogene laherparepvec or any of the other ingredients in this medicine (including disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, myo-inositol, or sorbitol)
- You have been told by your doctor that you have a severely compromised immune system
Patients with severely weakened immune systems face a higher risk of uncontrolled viral replication, which could lead to serious or life-threatening complications. This includes patients with conditions such as advanced HIV/AIDS, hematologic malignancies requiring active treatment, or those receiving high-dose immunosuppressive therapy. Your oncologist will evaluate your immune status before initiating Imlygic therapy.
Warnings and Precautions
Life-Threatening Herpes Infection
Because Imlygic is derived from herpes simplex virus type 1, there is a risk of life-threatening herpetic infection, including disseminated herpes—meaning the virus can potentially spread to parts of the body far from the injection site. If you develop any new or worsening symptoms during treatment, inform your healthcare provider immediately. Patients with a history of immunocompromise, HIV/AIDS, blood cancers, bone marrow cancers, or those taking corticosteroids or other immunosuppressive medications may be at higher risk for these complications.
Accidental Exposure and Transmission
Imlygic can potentially spread to other parts of your body and to other people through direct contact with bodily fluids or injection sites. To minimize the risk of transmission, the following precautions are essential during treatment and for up to 30 days after the last dose:
- Keep injection sites covered with airtight and watertight dressings at all times. If a dressing loosens or falls off, replace it immediately with a new one following your healthcare provider's instructions.
- Do not touch or scratch injection sites.
- Ensure that your bodily fluids (such as blood and urine) and injection sites do not come into direct contact with close contacts. Use condoms during sexual activity and avoid kissing if either partner has an open cold sore.
- Dispose of all used dressings and cleaning materials in a sealed plastic bag before discarding in household waste.
Close contacts who accidentally come into contact with Imlygic should wash the affected area thoroughly with soap and water and/or a disinfectant. If they develop signs or symptoms of herpes infection, they should seek medical attention promptly. Testing can be arranged through your healthcare provider to determine whether the infection is related to Imlygic.
Protection of Vulnerable Close Contacts
Special care must be taken to protect certain vulnerable individuals from any potential exposure to Imlygic. Pregnant close contacts, immunocompromised individuals, and newborn babies must not touch injection sites, used dressings, or cleaning materials. These populations are at particular risk for serious complications if exposed to the live modified virus contained in Imlygic.
Herpes Infection During Treatment
Cold sores or more serious herpes infections may occur during or after treatment with Imlygic. Signs and symptoms can include pain, burning, or tingling in blisters around the mouth, genitals, fingers, or ears; eye pain; light sensitivity; watery eyes; blurred vision; weakness in the arms or legs; extreme drowsiness; and confusion. If you experience any of these symptoms, follow standard hygiene practices to prevent viral spread and contact your healthcare provider.
Injection Site Infection and Delayed Healing
Imlygic can cause infection at the injection site. Signs include pain, redness, warmth, swelling, discharge, or sores, as well as fever and chills. Healing at the injection site may take longer than normal. Keep the wounds clean and covered with dressings to minimize the risk of bacterial infection (cellulitis). Report any signs of injection site infection to your doctor promptly.
Autoimmune Reactions
Imlygic can trigger autoimmune reactions—situations where the body's immune system overreacts and attacks its own tissues. Reported autoimmune complications include glomerulonephritis (inflammation of the kidneys), vasculitis (narrowing or blockage of blood vessels), pneumonitis (swelling in the lungs), worsening of psoriasis, and vitiligo (areas of skin that lose their color). Inform your healthcare team if you have a history of autoimmune disease before starting treatment.
Plasmacytoma
In rare cases, Imlygic may cause an accumulation of abnormal white blood cells near the injection site, known as plasmacytoma. Tell your doctor if you have a current or past history of blood cancer, including multiple myeloma, before beginning treatment.
Airway Compromise
If you have a tumor located on or near the neck, your doctor may warn you that your airway could feel constricted during treatment. This is an important consideration that will be monitored during your treatment sessions.
Patients Without Prior Herpes Infection
If you have never had a herpes infection before, you are more likely to experience fever, chills, and flu-like symptoms during the first six treatment sessions. This is because your immune system has no prior exposure to HSV-1, meaning your body will mount a stronger initial immune response to the virus. These symptoms typically become less severe as treatment progresses.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving Imlygic. This medication may harm the unborn baby. Women of childbearing potential should use effective contraception throughout the duration of treatment. Discuss suitable contraceptive methods with your healthcare provider.
It is not known whether Imlygic passes into breast milk. If you are breastfeeding or planning to breastfeed, talk to your doctor. Together you will decide whether to discontinue breastfeeding or to stop Imlygic treatment, taking into account the benefit of breastfeeding for the child and the benefit of treatment for you.
Use in Children and Adolescents
The use of Imlygic has been studied in children and young adults aged 7 to 21 years with advanced non-central nervous system tumors suitable for direct injection. However, Imlygic has not been studied in children younger than 7 years of age. The safety and efficacy profile in pediatric populations remains limited, and its use in these patients should be carefully considered on an individual basis by the treating oncologist.
Driving and Operating Machinery
During treatment with Imlygic, you may experience symptoms such as dizziness or confusion. These effects could impair your ability to drive or operate machinery. Exercise caution until you are confident that Imlygic does not affect you adversely. If you experience significant dizziness, confusion, or fatigue following an injection, do not drive or operate heavy machinery until the symptoms have fully resolved.
How Does Imlygic Interact with Other Drugs?
Because Imlygic is a live modified virus, its interactions with other medications differ from those of traditional chemotherapy drugs. The most clinically significant interactions involve medications that can either reduce the effectiveness of the virus or increase the risk of uncontrolled viral replication. Tell your healthcare provider about all medicines you are taking, have recently taken, or might take.
Antiviral Medications
Antiviral agents used to treat or prevent herpes infections—such as acyclovir, valacyclovir, and famciclovir—can directly interfere with Imlygic's mechanism of action. These drugs work by inhibiting viral replication, which means they could prevent Imlygic from multiplying within tumor cells and achieving its therapeutic effect. If you are taking antiviral medications, your doctor will need to carefully consider the timing and necessity of these treatments in relation to your Imlygic therapy.
Immunosuppressive Agents
Corticosteroids and other immunosuppressive medications may increase the risk of serious herpes infection complications. At the same time, immunosuppression may theoretically reduce the immune-mediated antitumor response that Imlygic is designed to stimulate. Your oncologist will carefully weigh the risks and benefits if you require immunosuppressive therapy during Imlygic treatment.
| Interacting Drug/Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Acyclovir, Valacyclovir, Famciclovir | Major | May reduce Imlygic's antitumor efficacy by inhibiting viral replication | Avoid concurrent use; discuss timing with oncologist |
| Systemic corticosteroids (e.g., prednisone) | Major | Increased risk of disseminated herpes infection; reduced immune-mediated antitumor effect | Use with extreme caution; monitor closely |
| Other immunosuppressants (e.g., methotrexate, cyclosporine) | Major | Increased risk of uncontrolled viral replication and serious infection | Assess immune status; may be contraindicated |
| Checkpoint inhibitors (e.g., pembrolizumab, nivolumab) | Moderate | May enhance immune-related adverse effects; potential synergistic antitumor activity | Under clinical investigation; close monitoring required |
| TNF-alpha inhibitors (e.g., infliximab, adalimumab) | Major | Significant immunosuppression; increased viral dissemination risk | Generally avoid; consult specialist |
Ongoing clinical trials are investigating the combination of Imlygic with immune checkpoint inhibitors such as pembrolizumab (Keytruda) and ipilimumab (Yervoy). Early data from the MASTERKEY-265 trial (Imlygic plus pembrolizumab) showed promising response rates in patients with advanced melanoma. However, these combinations may also increase the frequency of immune-related adverse events and should only be used under close medical supervision in a clinical trial or approved setting.
What Is the Correct Dosage of Imlygic?
Imlygic is administered exclusively by healthcare professionals in a clinical setting. The drug is injected directly into accessible melanoma tumors using a syringe and needle in a procedure known as intralesional injection. You should never attempt to administer this medication yourself.
Adults
Initial Dose (Day 1)
Up to 4 ml of Imlygic at a concentration of 106 (1 million) PFU/ml is injected into the tumor(s). The lower starting concentration allows the immune system to begin developing a response to the modified virus before exposure to the higher therapeutic dose.
Second Dose (Week 3)
Up to 4 ml of Imlygic at the higher concentration of 108 (100 million) PFU/ml is injected 3 weeks after the first dose. This 3-week interval between the first and second dose is specifically designed to allow seroconversion in patients who are HSV-1 seronegative.
Subsequent Doses (Every 2 Weeks)
Up to 4 ml of Imlygic at a concentration of 108 (100 million) PFU/ml is injected every 2 weeks thereafter. Treatment continues for at least 6 months, or longer, as long as injectable tumors remain. The treating physician decides which tumors to inject at each visit—not all tumors may be injected at every session.
| Treatment Phase | Concentration | Maximum Volume | Timing |
|---|---|---|---|
| Initial dose | 106 PFU/ml (1 million) | Up to 4 ml | Day 1 |
| Second dose | 108 PFU/ml (100 million) | Up to 4 ml | 3 weeks after first dose |
| Subsequent doses | 108 PFU/ml (100 million) | Up to 4 ml | Every 2 weeks |
The injection volume for each individual tumor is determined based on tumor size. Your healthcare provider will prioritize which lesions to inject based on clinical assessment. During treatment, existing tumors may grow larger and new tumors may develop. This does not necessarily mean the treatment is failing—these changes can occur as part of the inflammatory immune response triggered by Imlygic. Your oncologist will evaluate overall treatment response over the course of therapy.
Children and Adolescents
Limited data are available for Imlygic use in pediatric patients aged 7 to 21 years. In studies of children and young adults with advanced non-central nervous system tumors, the dosing approach was similar to that used in adults. However, Imlygic has not been studied in children under 7 years of age. Pediatric dosing should be determined by the treating oncologist on an individual basis.
Elderly Patients
No specific dose adjustment is required for elderly patients. In the pivotal OPTiM clinical trial, patients aged 65 years and older received the same dosing regimen as younger adults. However, elderly patients may be more susceptible to side effects such as fatigue, dehydration, and flu-like symptoms and should be monitored accordingly during treatment.
Missed Dose
It is important to attend all scheduled appointments for Imlygic treatment. If you miss an appointment, contact your healthcare provider as soon as possible to reschedule. The timing of your next dose will be determined by your doctor based on how long it has been since your last injection. Do not attempt to make up for a missed dose by receiving a double dose.
Overdose
Because Imlygic is administered by healthcare professionals in a controlled clinical environment, overdose is unlikely. There are no specific reports of Imlygic overdose in clinical literature. If an overdose were to occur, the patient would be monitored closely and treated symptomatically. There is no specific antidote for Imlygic, though antiviral medications such as acyclovir could theoretically be used to limit viral replication in an emergency situation.
What Are the Side Effects of Imlygic?
Like all medicines, Imlygic can cause side effects, although not everyone who receives it will experience them. Keeping injection sites clean and covered with dressings helps minimize the risk of bacterial infections at the injection site (cellulitis). Flu-like symptoms, fever, and chills are commonly observed and generally subside within the first 72 hours after treatment.
Very Common
May affect more than 1 in 10 people
- Flu-like symptoms, fever, chills, fatigue, pain
- Injection site reactions: pain, redness, bleeding, swelling, inflammation, discharge, warmth
- Nausea, vomiting, diarrhea, constipation
- Headache
- Muscle pain (myalgia), joint pain/swelling (arthralgia), pain in arms and/or legs
- Cough
- Swelling of tissue (peripheral edema)
Common
May affect up to 1 in 10 people
- Bacterial infection (cellulitis), cold sores (oral herpes)
- Tumor pain, infected tumor
- Anemia (fatigue, headache, dizziness, pallor)
- Dehydration
- Confusion, anxiety, depression, dizziness, insomnia
- Pain in ears, throat, abdomen, groin, back, and armpit
- Rapid heart rate at rest (tachycardia), high blood pressure (hypertension), facial flushing
- Deep vein thrombosis (pain, swelling, warmth in a leg or arm from a blood clot)
- Shortness of breath (dyspnea), upper respiratory infection
- Abdominal discomfort
- Vitiligo (colorless skin areas), rash, dermatitis
- Weight loss, general malaise
- Wound complications, bruising, post-treatment pain
- Immune-related: vasculitis (fever, fatigue, weight loss, muscle/joint pain), pneumonitis (breathlessness, cough, fatigue), worsening psoriasis, glomerulonephritis (pink/tea-colored urine, foamy urine, high blood pressure, fluid retention)
Uncommon
May affect up to 1 in 100 people
- Injection site infections
- Plasmacytoma (tumor of white blood cancer cells growing at or near the injection site)
- Herpes keratitis (eye infection caused by herpes)
- Airway obstruction
- Allergic reaction (hypersensitivity)
Rare / Post-Marketing
May affect fewer than 1 in 1,000 people
- Disseminated herpes infection (life-threatening spread of virus to distant body sites)
- Severe systemic immune reactions
If you experience any side effects, including any not listed above, talk to your healthcare provider. Prompt reporting of adverse effects is important for the ongoing safety monitoring of Imlygic. You can also report suspected side effects directly to your national health authority or to the European Medicines Agency (EMA).
In clinical trials, the majority of patients experienced flu-like symptoms and injection site reactions, particularly during the early phases of treatment. These side effects generally became less severe with subsequent treatment cycles. Patients who had never had a previous herpes infection were more likely to experience fever, chills, and flu-like symptoms during the first six treatments. Adequate hydration, rest, and over-the-counter pain relievers (as recommended by your doctor) can help manage these symptoms.
How Should Imlygic Be Stored?
Imlygic is stored and handled exclusively by healthcare professionals at your treatment facility. As a patient, you will not need to store this medication at home. However, understanding the storage requirements can provide insight into the careful handling this biological therapy requires.
The medication must be stored and transported in a frozen state at extremely low temperatures between −90°C and −70°C (−130°F to −94°F). This ultra-low temperature requirement is necessary to maintain the viability of the modified virus. Vials must be kept in their original packaging to protect them from light, as the medication is light-sensitive.
Thawing Procedure
Before administration, frozen Imlygic vials are thawed at room temperature (20°C to 25°C). Complete thawing typically takes 30 to 70 minutes depending on the ambient temperature. The vials should be gently swirled but never shaken, as vigorous agitation could damage the viral particles. Once thawed, Imlygic should be administered as soon as practically possible.
| Storage Temperature | 106 PFU/ml | 108 PFU/ml |
|---|---|---|
| 2°C to 8°C (syringe) | 8 hours | 8 hours |
| Up to 25°C (syringe) | 2 hours | 4 hours |
| 2°C to 8°C (total: vial + syringe) | 24 hours | 7 days |
| Up to 25°C (total: vial + syringe) | 12 hours | 24 hours |
Imlygic must not be refrozen once thawed. Any thawed medication that has been stored beyond the specified time limits must be discarded. The medicine contains genetically modified organisms, and local regulations for the handling and disposal of such materials must be followed. Healthcare facilities use specialized waste management protocols for Imlygic and any materials that come into contact with it.
The vial caps are color-coded for safety: the 106 PFU/ml concentration has a light green cap, while the 108 PFU/ml concentration has a royal blue cap. This visual distinction helps healthcare professionals quickly identify the correct concentration during preparation and administration.
What Does Imlygic Contain?
Active Ingredient
Each single-use vial contains 1 ml of solution at a nominal concentration of either 1 × 106 (1 million) plaque-forming units (PFU)/ml or 1 × 108 (100 million) PFU/ml of talimogene laherparepvec. The active substance is a live, attenuated herpes simplex virus type 1 (HSV-1) that has been genetically modified to selectively replicate in tumor cells and produce human GM-CSF.
Inactive Ingredients (Excipients)
- Disodium phosphate dihydrate
- Sodium dihydrogen phosphate dihydrate
- Sodium chloride
- Myo-inositol
- Sorbitol (E420)
- Water for injections
Sodium and Sorbitol Content
Each 1 ml vial contains 7.7 mg of sodium, which is equivalent to approximately 0.4% of the WHO recommended maximum daily sodium intake for adults. The vial also contains 20 mg of sorbitol per 1 ml. Patients with hereditary fructose intolerance should inform their healthcare provider, as sorbitol is a source of fructose.
Appearance and Packaging
Imlygic is supplied as a clear to semi-transparent liquid (106 PFU/ml) or semi-transparent to opaque liquid (108 PFU/ml). The solution is provided in a single-use 1 ml vial made of cyclic olefin polymer plastic with a chlorobutyl elastomer stopper and aluminum seal with a polypropylene snap-off cap. The vial cap is color-coded: light green for 106 PFU/ml and royal blue for 108 PFU/ml. The medication does not contain preservatives.
Frequently Asked Questions About Imlygic
Medical References and Sources
This article is based on current medical research and international regulatory documents. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA) (2025). "Imlygic – Summary of Product Characteristics." EMA EPAR – Imlygic Official European regulatory assessment and product information for Imlygic.
- U.S. Food and Drug Administration (FDA) (2024). "IMLYGIC (talimogene laherparepvec) – Prescribing Information." FDA – Imlygic U.S. regulatory prescribing information and safety data for Imlygic.
- Andtbacka RHI, et al. (2015). "Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma." Journal of Clinical Oncology. 33(25):2780-2788. doi:10.1200/JCO.2014.58.3377 Pivotal OPTiM phase III trial demonstrating improved durable response rate with T-VEC in advanced melanoma. Evidence level: 1B.
- National Comprehensive Cancer Network (NCCN) (2025). "NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous." NCCN Guidelines Comprehensive clinical practice guidelines for melanoma management, including T-VEC recommendations.
- Ribas A, et al. (2017). "Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy." Cell. 170(6):1109-1119. doi:10.1016/j.cell.2017.08.027 Key study demonstrating T-VEC's ability to enhance anti-PD-1 immunotherapy efficacy through immune priming.
- Chesney JA, et al. (2023). "Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis." Journal for ImmunoTherapy of Cancer. 11(1):e006270. Long-term follow-up data for T-VEC combination therapy in advanced melanoma.
- European Society for Medical Oncology (ESMO) (2024). "Cutaneous Melanoma: ESMO Clinical Practice Guidelines." ESMO Guidelines European clinical practice guidelines for the management of cutaneous melanoma.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines." WHO Essential Medicines List WHO reference for essential medicine classifications and global treatment standards.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. The pivotal clinical trial data (OPTiM) represents Level 1B evidence from a large, well-conducted randomized controlled trial.
iMedic Medical Editorial Team
Specialists in oncology, immunotherapy and dermatologic oncology
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic background and clinical experience. Our editorial team includes:
Oncology Specialists
Licensed physicians specializing in medical oncology and dermatologic oncology, with documented experience in melanoma treatment and immunotherapy.
Researchers
Academic researchers with published peer-reviewed articles on cancer immunotherapy and oncolytic virotherapy in international medical journals.
Clinicians
Practicing physicians with extensive clinical experience treating patients with advanced melanoma using immunotherapy and targeted therapy.
Medical Review
Independent review panel that verifies all content against international medical guidelines and current research from EMA, FDA, and NCCN.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence in oncology
- Members of ESMO (European Society for Medical Oncology) and other professional bodies
- Documented research background with publications in peer-reviewed journals
- Continuous education according to NCCN, ESMO, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer review before publication. iMedic receives no commercial funding from pharmaceutical companies.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in oncology, immunology, dermatology, and internal medicine.